

AMENDMENTS TO THE CLAIMS

1. (Currently Canceled)

2. (Canceled)

3. (Currently Canceled)

4. (Currently Canceled)

5. (Canceled)

6. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, and wherein said fragment comprises an ELR motif ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises~~ and an amino acid sequence that is at least 70% identical to an N-terminal amino acid sequence of IL-8, and is no greater than about 15 amino acids in length, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5 or residues 1-38 of SEQ ID NO.: 4.

7. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, and wherein said fragment comprises an ELR motif and ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence that is at least 90% identical to an N-terminal amino acid sequence of IL-8, and is no greater than about 15 amino acids in length, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5 or residues 1-38 of SEQ ID NO.: 4.~~

8. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, The polypeptide of claim 7, wherein the IL-8 fragment comprises an amino acid sequence selected from

C1 the group consisting of SEQ ID NO:8 and SEQ ID NO:9, and is no greater than about 15 amino acids in length.

9-18. (Canceled)

19. (Currently Canceled)

20-86. (Canceled)

87. (Currently Amended) The polypeptide of claim ~~1~~ 6, 7, or 8, wherein the polypeptide is a cyclic polypeptide.

88. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises~~ consists of the amino acid sequence SAKELR (SEQ ID NO.: 8).

C2 89. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, comprises an ELR motif, and is no greater than about 15 amino acids in length, and ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of SAKELR (SEQ ID NO.: 8), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the SAKELR (SEQ ID NO.: 8).~~

90. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises~~ consists of the amino acid sequence AVLPRSAKELR (SEQ ID NO.: 9).

91. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, comprises an ELR motif, and is no greater than about 15 amino acids in length, and ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of AVLPRSAKELR (SEQ ID NO.: 9), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the AVLPRSAKELR (SEQ ID NO.: 9).~~

92. (Previously Added) A composition comprising the polypeptide of claim 88, 89, 90 or 91 and a pharmaceutically acceptable carrier.

93. (Previously Added) The polypeptide of claim 88, 89, 90 or 91, wherein the polypeptide is a cyclic polypeptide.

94. (New) The composition of claim 6, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-36 of SEQ ID NO.: 5.

95. (New) The composition of claim 6, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-38 of SEQ ID NO.: 4.

96. (New) The composition of claim 6, wherein said fragment is no greater than about 8 amino acids in length.

97. (New) The composition of claim 7, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-36 of SEQ ID NO.: 5.

98. (New) The composition of claim 7, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-38 of SEQ ID NO.: 4.

99. (New) The composition of claim 7, wherein said fragment is no greater than about 8 amino acids in length.

100. (New) The composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 8.

101. (New) The composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 9.